Breakthrough in understanding lung cancer vulnerabilities points the way to new targeted therapy

October 1, 2012, University of Sheffield

More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study.

Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types – paving the way for clinical trials of new targeted treatments which could revolutionise the current approach.

Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases.

Unfortunately, the prognosis for SCLC patients is very bleak – two thirds of people are diagnosed in the late stages of the disease when the five year survival rate with current treatments is less than five per cent.

But now researchers have discovered that survival of SCLC cells grown from human tumours relies upon a protein called Aurora kinase. This finding, published today in the journal Proceeding of the National Academy of Sciences (PNAS), suggests that 'targeted' therapeutic strategies should focus on testing Aurora kinase inhibitors, several of which have already been developed by pharmaceutical companies.

The team also went on to show that Aurora kinase inhibitors are most effective at killing SCLC cells when the cells have high levels of the MYC . This predicts that these drugs might be most beneficial for SCLC patients with a MYC , which is found in up to seven per cent of people diagnosed with SCLC.

Dr Patrick Eyers, from the University of Sheffield's Institute for , said: "A major goal of modern cancer research is to discover drugs that vulnerabilities in specific sub-populations. Current chemotherapy for SCLC kills and non-cancerous cells indiscriminately and results in severe side effects.

"However, revolutionary clinical trials have recently validated 'molecularly targeted' kinase inhibitors for treating cancers such as melanoma, leukaemia and non-small cell lung cancer.

"We have been studying Aurora kinase inhibitors for several years, and the remarkable vulnerability of some SCLC-derived cells to such drugs can hopefully be rapidly confirmed by careful stratification of SCLC patients and their enrolment in new clinical trials."

Explore further: Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma

Related Stories

Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma

June 15, 2012
Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with ...

A new approach to cancer treatment published

October 10, 2011
(Medical Xpress) -- Scientists have discovered a mechanism that causes an aggressive type of lung cancer to re-grow following chemotherapy, offering hope for new therapies.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.